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ABSTRACT
Distal extremity wounds are a significant clinical problem in horses and humans and may benefit
from mesenchymal stem cell (MSC) therapy. This study evaluated the effects of direct wound treat-
ment with allogeneic stem cells, in terms of gross, histologic, and transcriptional features of heal-
ing. Three full-thickness cutaneous wounds were created on each distal forelimb in six healthy
horses, for a total of six wounds per horse. Umbilical cord-blood derived equine MSCs were
applied to each wound 1 day after wound creation, in one of four forms: (a) normoxic- or (b)
hypoxic-preconditioned cells injected into wound margins, or (c) normoxic- or (d) hypoxic-
preconditioned cells embedded in an autologous fibrin gel and applied topically to the wound bed.
Controls were one blank (saline) injected wound and one blank fibrin gel-treated wound per horse.
Data were collected weekly for 6 weeks and included wound surface area, thermography, gene
expression, and histologic scoring. Results indicated that MSC treatment by either delivery method
was safe and improved histologic outcomes and wound area. Hypoxic-preconditioning did not
offer an advantage. MSC treatment by injection resulted in statistically significant increases in
transforming growth factor beta and cyclooxygenase-2 expression at week 1. Histologically, signifi-
cantly more MSC-treated wounds were categorized as pro-healing than pro-inflammatory. Wound
area was significantly affected by treatment: MSC-injected wounds were consistently smaller than
gel-treated or control wounds. In conclusion, MSC therapy shows promise for distal extremity
wounds in horses, particularly when applied by direct injection into the wound margin. STEM
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SIGNIFICANCE STATEMENT
Distal extremity wounds are a significant clinical problem in horses and humans and may bene-
fit from mesenchymal stem cell (MSC) therapy. This study evaluated the effects of direct wound
treatment with allogeneic stem cells. This study provides evidence that MSC therapy shows
promise for distal extremity wounds in horses, particularly when applied by direct injection into
the wound margin. Interestingly, hypoxic preconditioning did not offer an advantage in this
study. These findings in a horse model may be directly applicable to chronic wound studies in
human patients, and provide insights to cellular based approaches of treatment.
INTRODUCTION
Chronic wound management is a growing prob-
lem for human health care around the world [1,
2]. Full thickness wounds and extensive burns are
extremely detrimental to patients even with early
intervention [3]. Traumatic wounds also com-
monly occur in the distal limbs of horses and heal-
ing is often delayed, due to high skin tension, and
minimal subcutaneous stroma for vascular and
structural support, and an aberrant inflammatory
response. The pathobiology occurring in equine
distal limb wounds is characterized by prolonged
but somewhat ineffectual inflammation [4, 5],
persistent transforming growth factor beta 1
(TGFb1) signaling leading to a fibroproliferative
response [6], and regional hypoxia with microvas-
cular occlusion [7–10]. Epithelialization is slow
and there is minimal capacity for wound contrac-
tion in this location. Taken together, these factors
result in a delayed and often dysplastic healing
process [11], as is the case for many human
patients as well. Both species demonstrate
hypoxia and delayed or absent epithelialization in
distal extremity wounds, and horses have been
proposed as a translational model for human
wound research [12]. The development of new
methods to augment healing in distal extremity
wounds could have significant clinical impact for
both horses and people.
aDepartment of Pathology,
Microbiology, Immunology,
School of Veterinary
Medicine, University of
California, Davis, Davis,
California, USA; bDepartment
of Veterinary Surgical and
Radiological Sciences, School
of Veterinary Medicine,
University of California,
Davis, Davis, California, USA
Correspondence: Dori L.
Borjesson, D.V.M., Ph.D.,
Director, Veterinary Institute for
Regenerative Cures, Department
of Pathology, School of
Veterinary Medicine, UC Davis,
Davis, California 95616, USA.
Telephone: (530) 754-5202;
e-mail: dlborjesson@ucdavis.edu
ReceivedMarch 29, 2017;
accepted for publication August
25, 2017; first published October
24, 2017.
http://dx.doi.org/
10.1002/sctm.17-0071
This is an open access article
under the terms of the Creative
Commons Attribution-NonCom-
mercial-NoDerivs License, which
permits use and distribution in
any medium, provided the origi-
nal work is properly cited, the use
is non-commercial and no modifi-
cations or adaptations are made.
STEM CELLS TRANSLATIONALMEDICINE 2018;7:98–108 www.StemCellsTM.com Oc 2017 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL
TRANSLATION
Recent studies have demonstrated beneficial effects of mes-
enchymal stem cells (MSC) on wound repair in laboratory animals
[13–15] and in one case series of horses [16]. It has also been
reported that umbilical cord derived MSCs have improved burn
repair in rodent models [15, 17]. Preconditioning MSCs in a
hypoxic environment prior to tissue delivery appears to increase
prosurvival and proangiogenic gene expression [18, 19]. Since
these cells may improve neovascularization, reduce inflammatory
cytokines, and promote wound contraction [19], they may be of
particular benefit in the inherently hypoxic and persistently
inflamed distal limb wounds of horses. Several MSC delivery
methods have been reported, including intradermal injection [13,
16, 20] and topical application of cells within a synthetic [21] or
natural polymer construct [22], such as fibrin [3, 23, 24].
Autologous and allogeneic MSCs have been widely used in
both research and clinical applications in the horse, particularly in
the treatment of musculoskeletal tissues [25, 26]. Recent studies
have also reported stem cell therapy to improve equine wound
healing in vitro and in vivo [16, 27–29]. Multipotent cells have
been sourced from equine peripheral blood [16], bone marrow,
adipose tissue, tendon, umbilical cord blood and tissue [30], amn-
ion [31] and skin [32], and pluripotent cells have been obtained
from embryos or induced from fibroblasts and keratinocytes
[33–37]. Induced pluripotent cells of fetal origin have also been
directed into keratinocyte lineage with a view toward cultured
equine skin constructs [33]. Umbilical cord blood MSCs have been
well-characterized in our laboratory [38–40] and were selected for
this study based on their stability within fibrin gels during pilot
studies and their nitric oxide production [39], which could prove
advantageous in the hypoxic wound environment of the distal
extremity.
In this study, we evaluated the application of allogeneic cord-
blood derived MSCs to experimentally created distal limb wounds
in horses. We compared hypoxic to normoxic-preconditioning of
the cells, and also compared their delivery by direct injection ver-
sus topical application embedded within a fibrin gel. We hypothe-
sized that MSC-treated wounds would have improved outcomes
in wound area, thermography, gene expression, and histology
when compared to untreated controls. We further hypothesized
that hypoxic-preconditioned MSCs would be of greater benefit for
wound healing than normoxic MSCs.
METHODS
Animals
Six adult horses (three females, three castrated males) of varying
breeds (four Quarter Horses, two Warmbloods) and ages (range:
5–19 years; mean: 14 years) were selected for the study. Horses
were housed in outdoor individual stalls at the Center for Equine
Health, University of California, Davis and were examined prior to
enrollment to ensure they were healthy and free of any scars or
skin disease on the distal limbs. The study was conducted accord-
ing to an approved institutional animal care and use protocol.
Experimental Overview. Equine cord blood MSCs from one
allogeneic donor were expanded and cultured exactly as previ-
ously described; [40] cells were trypsinized and prepared for
wound treatment at passage 4–5. Cells were continued in culture
or transferred into fibrin gels, and were then either exposed to
hypoxic conditions or maintained in normoxia, before application
to wounds (Fig. 1). In vitro preparation began approximately 2
Figure 1. Experimental design. Banked cord blood mesenchymal stem cells from one donor were cultured and either embedded in fibrin
gels or suspended in phosphate-buffered saline for treatment of experimental wounds on the distal forelimbs of horses. Prior to wound appli-
cation, one gel and one culture flask were exposed to hypoxia (2% O2) for 24 hours. Injected treatments were randomized in terms of right
or left limb and proximodistal wound assignment, and the corresponding gel was applied to the corresponding wound on the opposite limb.
Control wounds were treated with the corresponding blank vehicle (gel or saline). Treatment was applied 24 hours after wound creation.
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weeks before wound treatment and data was collected weekly for
6 weeks thereafter (Supporting Information Fig. S1).
MSCs in Fibrin Gels
Autologous fibrinogen was isolated from each study horse for
fibrin gel preparation as described previously [41]. Centrifuga-
tion was applied with minimal acceleration and deceleration
and prostaglandin E1 (10 mg/ml) (Sigma, St. Louis, MO) was
added to plasma to prevent platelet activation. Precipitated
fibrinogen was dissolved in DPBS and quantified by a STA Com-
pact Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ).
Fibrin gels were prepared in six-well cell culture dishes (Falcon,
Becton Dickinson, Franklin Lakes, NJ). Each gel was 2.375 ml
total volume (approximately 2.5 mm thick), 9.5 cm2 in area,
and contained 20 mg/ml fibrinogen and 1.66 3 106 MSCs.
Blank control gels were prepared without MSCs. On day 7, half
of the gels were transferred to a 5% CO2, 2% O2 hypoxic incuba-
tor, and grown for 24 hours before application to wounds. Nor-
moxic and control gels remained in standard culture
conditions.
Based on in vitro pilot studies and reported doubling times for
cord blood cells [42], we estimated the cell population to be 10–
20 3 106 cells per gel after 8 days of incubation (i.e., at the time
of application to wounds). Cell viability in the gels was confirmed
by visual assessment on a light microscope, based on the observa-
tion of elongated cell morphology and refractility; migration from
the gel margin was also confirmed during pilot studies (Fig. 2A).
On the day of wound treatment, gels were lifted from wells in the
laboratory hood (Fig. 2B) and transferred onto a Telfa pad (Telfa
pad, Covidien, Minneapolis, MN) for transport to the horse hous-
ing facility.
MSCs for Injection
Twenty-four hours before wound treatment, half of the flasks
were transferred to a 5% CO2, 2% O2 hypoxic incubator. Cells
were trypsinized, washed, and resuspended to a final concentra-
tion of 17.53 106 cells per milliliter in saline. One milliliter of cells
was injected for each treatment; 1 ml injectable saline was used
as a vehicle control. The target cell dose was 15–20 3 106 cells;
the cell concentration for the first horse’s injection was 17.5 3
106 cells per milliliter and we therefore matched all subsequent
injections to that same concentration.
Wound Creation
Surgical wounding was performed under field anesthesia: after
placing a 14 g IV catheter in the left jugular vein, horses were
treated with phenylbutazone (2 g IV) and then premedicated with
xylazine (1 mg/kg IV). Anesthesia was induced with ketamine
Figure 2. Experimental execution. Cord blood mesenchymal stem cells (MSCs) from one donor were suspended in autologous fibrinogen
from each experimental subject to create fibrin gels. Pilot studies confirmed cell viability within the gels (calcein-ethidium staining) and
migration from the gel margins at 48 hours after gels were released from wells (A). On the morning of wound treatment, gels were released
from the well just prior to wound application (B). (Pink staining is a result of phenol red in cell culture medium.) Wounds were treated by
topical application of MSCs in fibrin gels (C) or by direct subcutaneous injection of MSCs in saline (D).
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(3 mg/kg IV) and diazepam (0.1 mg/kg IV) and was maintained
with repeat doses of xylazine (0.5 mg/kg IV) and ketamine
(1.5 mg/kg IV) every 10 minutes thereafter. Horses were posi-
tioned in lateral recumbency and the dorsomedial aspect of the
down limb was aseptically prepared. Three square full-thickness
skin wounds (2.5 cm3 2.5 cm, spaced 2.5 cm apart and vertically
aligned; Fig. 1) were created using a sterile adherent template and
a #10 scalpel blade. The limb was bandaged in standard fashion
(Telfa pad, roll gauze (Kling, Johnson & Johnson, New Brunswick,
NJ), cotton, brown gauze, VetWrap (3M, St. Paul, MN) and Elasti-
kon (Johnson & Johnson, New Brunswick, NJ)). The procedure was
repeated on the opposite forelimb.
Wound Treatment
Treatments were assigned as follows: MSC injection was randomly
assigned to the right or left limb, and then control, normoxic
MSCs, or hypoxic MSCs were each randomly assigned to one of
the three wounds on that leg. On the opposite forelimb, corre-
sponding MSC-fibrin gel treatments (control, normoxic, hypoxic)
were assigned to the corresponding wound (i.e., proximal, middle,
distal, respectively) (Fig. 1). Treatments were applied on day 1
after wounding; horses were sedated with 0.01 mg detomidine IV.
Gels were lifted from wells in the laboratory hood by gently rim-
ming the margin with a P200 pipette tip and then passing the tip
back and forth under one released edge. The pipette tip was
moved across the well under the gel in an advancing manner as
the gel was allowed to fold down on itself (Fig. 2B). Spatula-
tipped forceps were used to transfer the gel onto a Telfa pad (Telfa
pad, Covidien, Minneapolis, MN) set within a sterile individual
Petri dish for transport to the horse housing facility. Gels were
applied directly to the wound surface by handling the Telfa pad
(Fig. 2C), and were secured to the limb with a single circumferen-
tial wrap of Elastikon. The gels were placed to ensure full contact
with the wound bed and no overlap with the wound margin.
Injections were applied subcutaneously at the mid-point of each
border of the square wound: 0.25 ml was injected at each site
using a 25 g needle (Fig. 2D). Control wounds received either
saline injection or a blank fibrin gel with no MSCs.
Bandaging
For the first week post-wounding, wounds were bandaged contin-
uously, as previously described (changed on days 1 and 5). Ban-
dages were also temporarily applied for 24 hours after each
biopsy to control bleeding. For the remainder of the experiment,
wounds were left unbandaged with the intent of minimizing exu-
berant granulation tissue (EGT) formation.
Thermography
Thermal images were acquired using a Flir Vet T-420 thermogra-
phy camera (FLIR Systems, Inc., North Billerica, MA) at a consistent
distance of 1 m. A standard emissivity value of 0.98 was chosen
based on recently published equine studies [43]. Bandages were
removed 15 minutes before acquisition of thermal images, in an
environmentally controlled room. One dorsopalmar image of the
metacarpus was acquired per limb with the thermography camera
before treatment of day 1 wounds (Week 0, baseline), and at 1, 2,
3, 4, 5, and 6 weeks. Using the FLIR Systems’ software program
(FLIR Systems, Inc., Wilsonville, OR), standard delineated areas
were superimposed on saved digital thermal images at specific
wound sites (Fig. 3) to determine core and whole leg tempera-
tures. The operator was blinded to the management of the
wounds (gel vs. injection, normoxic vs. hypoxic).
Wound Surface Area
Digital photography of each forelimb was performed on seven
occasions beginning the day after wound creation and then
weekly for 6 weeks thereafter. On each occasion, a clipboard con-
taining horse identification, date, limb identification, and a metric
ruler was placed behind each limb and included in the photo-
graph. Each picture was taken parallel to the ground and included
all three wounds. Care was taken to ensure that the true margins
of each wound were completely visible (i.e., not obscured by
bleeding, exudate, or regrown hair); any obscuring exudate was
gently removed using a saline-soaked gauze prior to photography.
Images were calibrated to scale and were analyzed using Image J
[44] (www.imagej.net) to trace wound margins and calculate sur-
face area. Each wound area was then expressed as a percentage
of its original area on day 1 (just prior to treatment).
Figure 3. Thermography. (A): Thermographic data were analyzed according to core wound temperature (small square gates centered on
wounds) and overall Leg temperature (larger square gates). (B): A significant effect of time was detected for all groups (p< .0001). By 6
weeks, the difference between core wound and surrounding leg temperature is nearly zero, that is, temperature of the wound bed has nor-
malized. There was a significant decrease of temperature variation in wounds treated with mesenchymal stem cell (MSC) embedded gels and
injected MSCs at Week 6. Data are displayed as mean (SE). Week 0 data was collected on day 1 after wounding, prior to treatment applica-
tion. Symbols: * denotes statistically significant difference for Injection (*, p< .05; **, p< .01; ***, p< .001); # denotes statistically signifi-
cant difference for Gel (#, p< .05; ##, p< .01).
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Wound Biopsy
Biopsies were obtained weekly for 6 weeks beginning on Week 1
(day 8), immediately following wound photography. Biopsies were
taken beginning from the distal right vertical border on Week 1
and proceeded proximally on Weeks 2 and 3, such that there was
no overlap with the previous biopsy site. On Weeks 4–6 the same
procedures were repeated on the left vertical margin of the
wound. Prior to biopsy, horses were sedated (0.01 mg/kg detomi-
dine IV) and an assistant wearing latex gloves cleaned the wound
margins and adjacent skin with saline-soaked gauze. Surgeons
wearing non-sterile latex gloves injected local anesthetic (2% lido-
caine without epinephrine, 2 ml total) subcutaneously through
the intact skin proximal and adjacent to the upper wound corner
above the intended biopsy site. Biopsies were then collected using
sterile technique: the 8 mm skin biopsy punch was centered on
the wound margin in order to obtain 1=2 wound bed and 1=2 adja-
cent intact skin in each biopsy. Samples were then cut in half
transversely: 1=2 was placed in formalin for histology and the other
1=2 was used for PCR analysis. For the PCR samples, intact skin was
removed and the remaining wound bed portion was cut into
approximately 4 pieces, placed in cryovials containing RNAlater
(Qiagen, Valencia, CA) and frozen at2808C.
Gene Expression
Biopsy samples were thawed, minced, and washed with DPBS
prior to cell lysis in modified (1% b-Mercaptoethanol) RLT buffer
(Qiagen). Tissues were then placed in a preheated (558C) water
bath sonicator (Branson, Shelton, CT) for 10 minutes. Lysed tissues
were further run through a QIAshredder column (Qiagen) per
manufacturer’s instructions. Tissue lysate was centrifuged, super-
natant was removed and subjected to RNA extraction with RNeasy
mini-kit (Qiagen) per manufacturer’s instructions. Extracted RNA
was then converted to cDNA using a First-strand cDNA Synthesis
kit (Origene, Rockville, MD) per manufacturer’s instructions. Quan-
titative reverse transcriptase-polymerase chain reaction (qRT-PCR)
was performed using primers that were purchased from a com-
mercial vendor (TGFb1, Kingfisher Biotech, Saint Paul, MN) or
designed via on-line software (peptidylpropyl isomerase B, cyclo-
oxygenase 2 [COX2], vascular endothelial growth factor [VEGF],
and basic fibroblast growth factor 2 [FGF2], www.idtdna.com. See
Supporting Information Table 1 for primers’ details), and Fast SYBR
Green Master MIX (AB Applied Biosystems, Foster City, CA) and
run on a 7300 Real Time PCR System (AB Applied Biosystems)
thermocycler. All PCR products sizes were confirmed by electro-
phoresing PCR products on a 2% agarose gel. Gene expression
data were reported as fold-change over corresponding controls
from each time point.
Histology
Biopsies were processed for routine H&E-stained tissue sections.
Tissue sections were randomly assigned a number value and
blindly evaluated by a board-certified veterinary pathologist.
Sections were scored 0–4 for each of four categories: degree of
epithelialization, inflammation, vascularity, and fibrosis. For all
scores, 0 was assigned to cases lacking the histologic feature, and
4 was assigned when the feature was prominent.
Statistical Analysis
Significance for all analyses was set at p< .05 and data were
reported as mean1/– SE.
For wound area, thermography, and gene expression, three
dependent variables were considered; treatment of wound by
MSC, hypoxic preconditioning, and modality of MSC application.
Data were analyzed using R software. Due to the small sample
size of the current study, data was log-transformed to achieve nor-
mality. A Wilk-Shapiro test of normality revealed all transformed
data sets had error distributions within a normal range
(W> 0.95). An ANOVA using a mixed model procedure was per-
formed to assess the array of treatments fixed effects by MSCs,
oxygen and application. No effects of hypoxic preconditions were
observed, therefore groups were combined to compare injection
versus gel over a 6-week time frame. Statistical outliers were
removed, only if alterations were suspect of causation by auto-
mutilation. Finalized data were analyzed using GraphPad Prism 6
for Mac OS X. Ordinary two-way ANOVA testing was performed to
detect significant differences between treatment groups over
time. Repeated measures could not be performed due to removal
of experimental wounds from data sets caused by self-mutilation
by some study animals. Using the Sidak multiple comparison test,
post-tests were performed to first compare treatment groups at
each time point and then to compare all time points within each
treatment group.
Histologic scores were entered into a matrix and blindly cate-
gorized by hierarchical clustering based on scores across all four
variables. Hierarchical clustering was performed using package
GMD in R software. In addition, the number of horses within each
group (MSC-treated vs. control) was tabulated and a Fisher’s exact
test was performed using R software.
RESULTS
Gross Wound Evaluation
All wounds healed and no adverse effects were noted specific to
MSC therapy. Pilot studies using continuous bandaging resulted in
significant EGT formation. This problem was largely eliminated
using the short-term and intermittent (i.e., after biopsy) bandag-
ing protocol as described in “Methods” section. However, in the
absence of protective bandages, fly irritation and self-mutilation
were confounding factors in some horses; four affected wounds
(two Injection, one Gel, and one Injection-Control) were excluded
from data analysis. Notably, gels were not grossly visible in the
wound bed at the first bandage change (day 5), suggesting proteo-
lytic digestion.
No Effect of Hypoxic Preconditioning on Wound
Healing Outcomes
Based on the existing literature and our pilot studies, which
showed altered gene expression after hypoxic preconditioning,
we expected to find a positive effect of hypoxic-MSC treatment.
Surprisingly, we did not detect significant differences in any out-
come on the basis of hypoxic versus normoxic MSC culture condi-
tions. Data were therefore combined and results are reported as
four groups (Injection, Injection-Control, Gel, Gel-Control).
Thermographic Imaging Tracked Wound Healing In Situ
In order to noninvasively evaluate wound physiology in vivo, we
used thermographic imaging to detect changes in blood flow
post-wounding. This complementary modality correlated well
with histologic assessment of vascularization. Core wound tem-
perature and leg temperature changed throughout the study as
102 Stem Cell Treatment of Wounds in Horses
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
we expected: core wound temperature increased overall, as vas-
cularization of the wound bed occurred. Surrounding leg tempera-
ture initially increased, during the acute inflammatory phase after
wounding, and then decreased as healing progressed and inflam-
mation subsided (Fig. 3). The difference between these two values
(“Leg-Core”) was calculated as an index of healing, that is, in the
absence of a wound, there would be no difference in temperature
at these two sites, and the Leg-Core value would therefore equal
zero. As healing progresses, therefore, the Leg-Core value should
trend toward zero. There was an overall significant effect of time
(p< .0001), that is, as wounds healed, they returned to the tem-
perature of the surrounding intact skin. MSC treated wounds
began to normalize temperature (delta leg-core approaching zero)
at Week 6 in both gel and injection groups (p< .01).
MSC Treatment Accelerates Reduction in Wound Area
Wounds initially enlarged in size, as expected for equine limb
wounds, and then reduced to 72% (controls), 78% (MSC-gel), and
53% (MSC-injected) of original wound area by Week 6 (Fig. 4). A
significant treatment effect was detected (p5 .039) but post hoc
multiple comparisons failed to further clarify this effect. Nonethe-
less, mean wound area was smallest in the Injected group for all
time points. A significant effect of time was also detected for
treated wounds but not for control wounds: wound area was sig-
nificantly less at Weeks 4, 5, and 6 for Injection and at Weeks 5
and 6 for Gel, in comparison to Week 1 values (largest wound
areas).
Gene Expression Varies After MSC Injection but Not Gel
Application
Injected MSCs clearly impacted gene expression within the
wound, suggesting that direct application into the tissue allowed
immediate interaction and functionality within the wound envi-
ronment. Alternatively, it is possible that the physical process of
injection alone resulted in activation of the MSCs and altered their
gene expression profile.
Transcriptional changes did not occur when cells were embed-
ded within a three-dimensional fibrin matrix and applied to the
wounds.
Cyclooxygenase 2 (COX-2) expression changed significantly
based on time and treatment. Specifically, a 20-fold increase in
COX-2 expression was observed at Week 1 after MSC injection
(Fig. 5). This value was significantly greater than after MSC gel
application at the same time point (p< .0001) and was also signif-
icantly greater than all subsequent time points for MSC injection
(p< .0001). In contrast, there were no significant differences in
COX-2 expression with MSC gels.
TGFb1 expression was also significantly altered after MSC injec-
tion but not after gel application: MSC injection significantly
increased expression of TGFb1 at Week 1 only, as compared to gel
application (p< .01). Expression of TGFb1 at Week 1 was also signif-
icantly higher than Weeks 3–6 after MSC injection (p< .05). No
alterations in TGFb1 expression occurred after MSC-gel application.
For VEGF and FGF, there were no significant differences based
on treatment or time. There was a notable inversion of VEGF
expression: MSCs embedded in gel were associated with a twofold
Figure 4. Wound area. Wound surface area was calculated from wound margins traced on calibrated digital images. (A): Example images of
the same wound on day 1 (left) and day 36 (right), with corresponding outlines of the same images. (B): Wound area decreased significantly
in Weeks 4–6 for mesenchymal stem cell (MSC) Injected wounds, compared to Week 1 values (largest wound area); wounds treated with
MSC Gel followed suit at Weeks 5–6 but to a lesser extent. Data is displayed as mean (SE). Symbols: * denotes statistically significant differ-
ence for Injection (*, p< .05; **, p< .01; ***, p< .001); # denotes statistically significant difference for Gel (#, p< .05; ##, p< .01).
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increase in expression at Week 1 and returned to control levels at
Week 2; MSC injection results were just the opposite. We were
surprised not to see a greater impact on VEGF expression, particu-
larly in light of improved histologic scores for vascularity with MSC
treatment and the known nitric oxide production of cord blood
MSCs [39].
MSC Treatment Improves Histologic Outcomes
Histologic appearances varied widely and ranged from early vascu-
larization, fibrosis, and epithelialization to chronic inflammation
and ulceration (Fig. 6). In order to identify trends within this large
data set, histologic scores were distributed in a dendrogram with
a heatmap matrix (Supporting Information Fig. 2) superimposed,
using assigned colors to illustrate clusters of data. The following
clusters of wound characteristics were identified: (1A) increased
vascularity and epithelialization (1B) increased fibrosis (“Pro-
Healing”), (2A) lack of epithelialization, or ulceration, and (2B)
increased inflammation (“Ulcerative/Pro-Inflammatory”). Although
significant differences could not be detected between Injected ver-
sus Gel treatment groups, there was a significantly greater number
of MSC-treated wounds (Injected and Gel combined) in the Pro-
Healing Group than in the Ulcerative/Pro-Inflammatory Group;
(Fig. 7; p5 .0136).
DISCUSSION
Chronic wounds represent an enormous burden for the individual
patient and society as a whole. The impact of this “silent
epidemic” is felt on many levels, from lost work days to perma-
nent disability (amputation) to death of the patient, and the eco-
nomic implications of chronic wound care are alarming ($25
billion annually in the U.S.) [1]. Impaired healing can occur in
severely injured normal tissue, such as a burn, or as a result of
comorbidities which create compromised tissue integrity, such as
decubital sores or diabetic foot ulcers (DFU). Distal limb wounds
in horses share many of the complexities of chronic wounds in
people, in that they heal mainly by epithelialization, rather than
contraction, and are persistently hypoxic and pro-inflammatory
during the healing period. This study adds to the accumulating evi-
dence [16, 29, 45–52] that allogeneic MSC therapy can facilitate
wound healing: MSC-treated wounds showed significant differen-
ces in wound area, gene expression and histologic scores. MSCs
are believed to impact wound healing by paracrine immunomodu-
latory, antifibrotic [50, 51] and anti-inflammatory effects [15, 39,
45, 46], enhanced neovascularization [15, 21], reversal of collagen
dysregulation [52], and in some reports, by transdifferentiation
and engraftment [13, 53].
We evaluated several variables in the preparation and applica-
tion of MSCs to wounds, including hypoxic-preconditioning and
topical versus injectable delivery methods. In contrast to several
other reports [18, 19], hypoxia during MSC culture was not advan-
tageous in our study. Our pilot studies indicated an obvious in
vitro effect of hypoxia on MSC gene expression (induction of VEGF
expression), but this did not translate into a detectable effect in
vivo.With regard to delivery method, we investigated direct injec-
tion of MSCs as the simplest means for applying these cells to
Figure 5. Gene expression. PCR Data (mean [SE]), expressed as fold-change over corresponding controls. One week after treatment, COX-2
and TGFb gene expression were significantly greater after mesenchymal stem cell (MSC)-Injection in comparison to MSC-Gels.Week 1 expres-
sion after Injection was also significantly greater than that measured in all subsequent weeks (COX-2) and Weeks 3–6 (TGFb). No significant
differences were detected for VEGF or FGF. Symbols: *, p< .05; **, p< .01; ****, p< .0001. Abbreviations: COX-2, cyclooxygenase-2; FGF,
fibroblast growth factor; TGFb, transforming growth factor beta; VEGF, vascular endothelial growth factor.
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tissue, but were also interested in the impact of MSCs in a hydro-
gel. Burns and DFUs are preferentially treated with some type of
biological matrix to provide a physical barrier as well as to
“instruct” or contribute to the wound bed directly with molecules
such as hyaluronic acid [54], or conceivably, resident cells [49].We
chose autologous fibrin to provide the most native provisional
matrix possible for each wound, as well as naturally occurring
adhesion motifs to allow MSC anchorage and interaction within
the gel. The MSCs in gels were applied to wounds in what we
believed to be a “primed” state for biological activity: they were
elongated, attached to a matrix, migrating, and presumably inter-
acting with other cells in the gel through signal transduction, in
contrast to the dissociated, recently trypsinized cells used for
injection. In a recent study, protein synthesis by MSC spheroids
improved dramatically when embedded in an RGD-modified algi-
nate gels, presumably based on the ability of the cells to interact
with the matrix [55]. Another study on MSCs in a PEGylated fibrin
system showed significant increases in vascularization in a burn
model, and MSCs also transmigrated from the gel into the wound
bed [49]. However, in our study MSC-injection appeared superior
to topical application of MSC-laden gels.Wounds treated by MSC-
injection showed an earlier decrease in wound area, and signifi-
cant differences in early TGFb1 and COX-2 gene expression were
detected in the injected but not the gel-treated wounds. Injection
was logistically easier when compared to gel preparation: signifi-
cantly less time and materials are required for injection and the
entire cell dose is delivered directly into the tissue. Our gels
Figure 6. Histology. Representative photomicrographs demonstrating the histologic scoring criteria for epithelialization, inflammation, vas-
cularity, and fibrosis. H&E staining, bar5 50 lm.
Figure 7. Histology results. Fisher’s exact results comparing the
proportion of mesenchymal stem cell (MSC)-Treated versus control
wounds classified as either Histologic Score Group 1 (Pro-Healing)
or Group 2 (Ulcerative/Pro-Inflammatory). MSC-treated wounds
comprised a significantly greater proportion of the Pro-Healing
Group (p5 .0136).
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appeared to be digested rapidly within the wound, such that the
MSCs may have been liberated faster than they could migrate into
tissue; gel modification to reduce proteolytic destruction (such as
PEGylation) may have changed our results.
We expected that MSC treatment would mitigate the pro-
longed inflammatory response that contributes to delayed healing
of equine limb wounds. Indeed, MSC-treated wounds had lower
histologic scores for inflammation and appeared to progress
through the stages of wound healing earlier than control wounds.
It was therefore initially surprising to observe a dramatic increase
in expression of COX-2 in MSC-injected wounds at Week 1. This
increased expression was early and transient in nature. Although
COX-2 and its eicosanoid products are hallmarks of inflammation,
they (specifically COX-2 and Prostaglandin E2) are also recognized
as critical components of early wound healing in multiple tissues
including skin [56–59]. The increased COX-2 gene expression in
our study appears to represent an amplification of this key signal
in the healing process, as stimulated by MSC injection. Further
research into COX-2 protein expression by MSCs or their paracrine
targets during wound repair, including the timing and spatial local-
ization of this event, may clarify the mechanism for our observed
MSC treatment effect.
TGFb1 dysregulation has been implicated in excessive scar for-
mation in people and EGT in the horse. This pro-fibrotic marker
has been extensively studied in the equine wound literature
[60–63], and is known to peak early in normal healing and then
subside. In contrast, TGFb1 persists in wounds healing with EGT
[6] and inhibits epithelialization [62].We found that TGFb1 expres-
sion was significantly increased (threefold) at Week 1 after MSC
injection, and then returned to control values. Interestingly, a
more intense burst of TGFb1 has been reported in wounds in
ponies than in horses, and has been proposed as an explanation
for the more rapid and uncomplicated healing that ponies exhibit
[63]. In that sense, an early but transient increase in TGFb1, as
observed here, may be a favorable event mediated by MSC treat-
ment of wounds. A recent study by Fang et al. [50] documented
paracrine suppression of the TGFb/SMAD pathway by microsomal
RNA released from umbilical cord tissue-derived MSC exosomes.
This fascinating phenomenon resulted in reduced myofibroblast
function and ultimately reduced scar production in vivo. Future
studies to investigate expression of the antifibrotic isoform, TGFb3
[6, 64] may reveal additional favorable matrix effects of MSCs or
MSC-derived treatment in wounds, as reported in other species
[23, 51]. Clinically, this could translate into less EGT production
and scarring, as suggested by other authors [27].
Extrapolation from acute, experimentally created wounds to
naturally occurring, traumatic, chronic, and dysplastic wound
encountered in the clinical patient is obviously an imperfect sci-
ence, and is an inherent limitation of most wound studies. None-
theless, the study of acute wounds can hopefully identify targets
and timing for early therapeutic intervention. Any favorable mod-
ulation of acute wound events may prevent complications from
developing in “at-risk” wounds, such as complex traumatic
wounds with extensive soft tissue deficit or wounds with reduced
regenerative capacity (i.e., burns or DFUs). The horse may be a
more critical translational model for wound research than the tra-
ditional murine model, based on the hypoxic nature and minimal
contraction of wounds on their distal limbs. Environmental chal-
lenges to wound healing were also present in our study, as horses
were housed outside during the summer months and wounds
were left largely unbandaged to avoid the confounding effect of
EGT. Fly irritation and self-mutilation occurred in several wounds,
which were eliminated from the data set and thereby reduced
study power. A positive treatment effect was still detected despite
these limitations, and this model perhaps better represented the
complicated wounds for which we aim to improve treatment.
Our study employed allogeneic cord blood MSCs from one
donor. We selected cord blood MSCs based on favorable culture
characteristics, the perceived greater pluripotency of cord blood
cells, nitric oxide production [39], greater gene expression changes
with cord blood cells than with bone-marrow-derived MSCs dur-
ing our pilot studies, and better physical characteristics and gel
stability with cord-blood cells than with bone-marrow-derived
MSCs. The clinical safety of allogeneic MSCs has been confirmed
in the horse [26, 38, 65] and comparable efficacy to autologous
cells for wound healing has been demonstrated in other species
[66]. However, some limitations to allogeneic cell use may exist: a
recent study reported a slight advantage of autologous MSCs over
allogeneic cells in terms of treatment effect on equine wounds
[27], and allogeneic cells do elicit some immune response
[67–69]. Nonetheless, allogeneic cells obviously provide logistical
advantages, such as a readily available supply of banked cells
(thereby preventing delays in treatment) and selection of cell lines
with favorable and consistent growth characteristics. Future work
in this field will no doubt be directed at optimizing donor-
recipient suitability and thereby, presumably, treatment response.
SUMMARY
Allogeneic cord blood cells enhanced early healing in this critical
wound model in horses. This effect was greater for cells delivered
by injection than for cells applied topically in fibrin gel. Hypoxic
preconditioning did not offer an advantage in this study.
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